Page Image

The HemOnc Pulse

Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Chadi Nabhan, MD, MBA, FACP, covering all topics in the world of hematologic oncology.

Exclusive Coverage of The HemOnc Pulse Live
Advertisement
Advertisement
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | May 30, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Listen Now
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 10, 2024
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 8, 2024
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 28, 2024
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 15, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | February 14, 2024
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Chadi Nabhan, MD, MBA, FACPHodgkin Lymphoma | January 4, 2024
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
Jerald Radich, MDAcute Myeloid Leukemia | January 17, 2024
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | December 14, 2023
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | December 14, 2023
The debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 19, 2023
Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 16, 2023
We saw patients [who] were going to die, and it saved their life and then it's gone and it's shocking," she explained.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 2, 2023
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | October 19, 2023
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Chadi Nabhan, MD, MBA, FACPMyeloma | October 5, 2023
Dr. Fonseca offers his thoughts on the future of multiple myeloma treatment and more.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | September 14, 2023
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 13, 2023
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | August 24, 2023
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | August 10, 2023
The changes brought about by molecular characterization have a profound impact on real-world clinical care for AML.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 27, 2023
Nitin Jain, MD, discusses the data on venetoclax combinations in CLL and key frontline treatment considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 7, 2023
Dr. Nowakowski discusses the L-MIND study and the "revolution in the treatment of DLBCL" in recent years.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | July 26, 2023
Naveen Pemmaraju, MD, discusses the rare, ultrarare, and forgotten blood cancers on this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Dr. Majhail explores strategies to improve access to CAR-T therapy.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 13, 2023
Drs. Vijenthira and Prica discuss their study and why its results differed from a similar study published in late 2022.

Updates From Other BCT Partners

Blood Cancer TalksMyeloma | May 30, 2024
Drs. Hira Mian and Manni Mohyuddin join the hosts of "Blood Cancer Talks" for an overview of myeloma maintenance therapy.
Blood Cancer TalksBlood Cancer Talks | April 18, 2024
Raajit Rampal, MD, PhD, and the "Blood Cancer Talks" hosts discuss the diagnosis and management of essential thrombocythemia.
Edward Cliff, MDBlood Cancer Talks | April 11, 2024
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
Blood Cancer TalksMyeloma | March 29, 2024
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
Blood Cancer TalksBlood Cancer Talks | March 28, 2024
Dr. Tefferi discussed choosing the right mentors, balancing the clinical and the research, and becoming a "master physician."
Blood Cancer TalksBlood Cancer Talks | February 27, 2024
Dr. Dispenzieri, of the Mayo Clinic, joins the "Blood Cancer Talks" hosts to discuss how to treat and manage AL amyloidosis.
Advertisement
Advertisement